-

12:20:25 PM

RHHBY Stock News

RHHBY - Roche Holding AG

01/24/22 10:50 AM

OTC : RHHBY

The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular ( nAMD ) and diabetic macular edema (DME) Across four studies, about half of eligible faricimab patients were able to go four months between treatments,

RHEA-AI

positive

01/24/22 10:05 AM

OTC : RHHBY

The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months

Genentech, a member of the Roche Group, today announced The Lancet has published two papers highlighting one-year results from four pivotal Phase III studies of faricimab, an investigational bispecific antibody, in wet, or neovascular, age-related macular degeneration and diabetic macular edema. Notably, about half of eligible faricimab patients were able...

RHEA-AI

very positive

01/12/22 1:00 AM

OTC : RHHBY

Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care

Roche launches the cobas ® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of

RHEA-AI

neutral

01/11/22 1:00 AM

OTC : RHHBY

Roche introduces cobas infinity edge, a new open digital ecosystem for point of care professionals, driving improved patient outcomes and operational efficiencies in healthcare

Roche’s new cloud-based platform connects patient test results, medical records and third-party applications, allowing professionals to monitor patients’ health, adjust treatment protocols, and make quick data-driven patient care decisions anytime, anywhere within and across clinical settings. The

RHEA-AI

neutral

12/24/21 3:00 PM

OTC : RHHBY

covid-19

Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States

Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwide The COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate,

RHEA-AI

positive

12/17/21 1:00 AM

OTC : RHHBY

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems. This

RHEA-AI

neutral

12/15/21 1:00 AM

OTC : RHHBY

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas® HIV-1, cobas® HBV, cobas®

RHEA-AI

neutral

12/14/21 9:00 AM

OTC : RHHBY

Roche’s Polivy combination reduced the risk of disease worsening or death by 27% in people with previously untreated aggressive form of lymphoma

Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated diffuse large B-cell lymphoma in more than 20 years, potentially transforming treatment for people with this disease Four out of ten people receiving the current standard of care for this type

RHEA-AI

neutral

12/13/21 1:03 AM

OTC : RHHBY

Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine

Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare Preparing DNA for sequencing libraries is complex and prone to human error, which can interfere with accurate sequencing results The new

RHEA-AI

neutral

12/13/21 1:00 AM

OTC : RHHBY, CHGCY

Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

Genentech, a member of the Roche Group, today announced results from an interim analysis of the Phase III HAVEN 6 study, which show Hemlibra ® demonstrated a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A without factor VIII inhibitors. The data were presented at the 63rd American Society of Hematology...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next